From 32 million to over 100 million annually, medical beauty demand has pushed peptide suppliers to become on-chain fund management experts—filling the gap left by traditional finance, quietly and without noise.

Jie Bi Network news reports that, according to a Chainalysis report, gray-market peptide drug suppliers have turned to using Bitcoin and stablecoins due to traditional payment restrictions. In the first quarter of 2026, related crypto funds inflows reached $32 million, up 159% from $12 million in the previous quarter, with an annualized scale exceeding $100 million. The report says demand for peptide products is driven by medical aesthetics and health trends, and some leading suppliers have adopted more professional on-chain fund management; the proportion of stablecoins in large transactions has increased significantly to reduce the risk of market volatility.